- US distributor transition period impacted 2023 revenue from MD19.
- Second vial production line completed installation and trial production but not yet GMP certified.
- Impact of external competition, regulatory environment, and overall business environment.
聯亞藥業股份有限公司
Greenhouse gas emissions & sustainability report data
Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2021 | 798 tons/year reduction in CO2 |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Completed the first greenhouse gas emission inventory report in 2022.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Obtain Taiwan BLA for UB-851 erythropoietin and optimize production costs.
- Obtain GMP certification for the second vial production line and start mass production.
- Expand international markets for existing products.
📅 Medium-term
- Obtain US FDA approval for MD27 and MD21.
- Expand CDMO business in the US and other international markets.
- Develop new products with niche markets and obtain US FDA approval.
🔭 Long-term
- Develop difficult generic drugs and new dosage forms.
- Introduce advanced technologies such as gene therapy and cell therapy.
- Strengthen the company's new drug development business and increase international exposure.